CDSCO UID MFG/IVD/2020/000014_a78e4b7b08890518c34050881b63862d_56ca4908dd1ad81fddffba3a108b1ed0EbraQik COVID-19 Rapid Antigen Test
- UID
- MFG/IVD/2020/000014_a78e4b7b08890518c34050881b63862d_56ca4908dd1ad81fddffba3a108b1ed0
- Device class
- Class C
- Brand name
- ERBAQIK Dengue Alpha NS1Ag
- License holder
- M/s.Transasia Bio-Medicals Ltd.
- Approving authority
- Central Drug Standards Control Organization, West Zone
- Product information
- ErbaQik COVID-19 Ag test is intended for self-testing at home for the detection of COVID-19 Antigen in human Nasopharyngeal Sample. This test is authorized and intended for non-prescription home use as self-test with the self-collected nasal specimens from individuals of age 18 years or older & with adult collected nasal specimen from individuals aged 2 years or older. The report is provided by ErbaQik App (ERBAQIK Dengue Alpha NS1Ag) and the results can be interpreted by the user
EbraQik COVID-19 Rapid Antigen Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2020/000014_a78e4b7b08890518c34050881b63862d_56ca4908dd1ad81fddffba3a108b1ed0. This device is marketed under the brand name ERBAQIK Dengue Alpha NS1Ag. The license holder is M/s.Transasia Bio-Medicals Ltd., and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.
This page provides the facts attached to this CDSCO registry row. Other records from the same license holder are available through the database search link without adding aggregation queries to this page. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.